Guerbet : Feedback from analysts' meeting, TP raised to € 39 vs € 29
>An almost all-time rebound in growth - By forecasting growth of at least 8% in 2024, Guerbet is breaking with several years of modest growth. Over the past 12 years, Guerbet has exceeded the 8% threshold only once. This level is attributable to a combination of factors: 1/ for the past 12 months, Guerbet has been able to pass on price increases in X-ray (55% of revenues), something we have not seen for more than ten years, 2/ in MRI (33% of revenues), not only has th...Guerbet is a French pharmaceutical group that develops, markets, and provides maintenance services for medical equipment and devices destined for diagnostic and interventional imaging. Co.'s portfolio comprises media solutions covering MRI, X-rays and products devoted to International Radiology and Theranostics and medical devices. Co. organizes its operation by product family covering Magnetic Resonance Imaging (MRI), X-rays (XR) and Interventional Radiology and Theranostics (IRT). The MRI family includes Dotarem® and Artirem®; Co.'s X-ray product family includes Xenetix®, Optiray®/Optiject®, Oxilan®, and Telebrix®; and the IRT product family has Lipiodol®, Bleu Patente V and Hexabrix®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.